3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
OTHER
4
INDUSTRY
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
14
Neoplasms
9
Advanced Breast Cancer
6
Endometrial Neoplasms
5
Recurrence
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Lobular
3
Carcinoma, Ductal, Breast
3
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Osteoporosis
2
Neoplasms by Site
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Breast Neoplasms, Male
2
Breast Diseases
2
Bone Diseases, Metabolic
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Osteitis Deformans
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
Letrozole
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled